EMAIL THIS PAGE TO A FRIEND

Journal of pharmaceutical and biomedical analysis

Development and validation of a GC/MS method for the simultaneous determination of levetiracetam and lamotrigine in whole blood.


PMID 25238568

Abstract

A sensitive and accurate gas chromatography-mass spectrometric method was developed and validated for the simultaneous determination of levetiracetam and lamotrigine in whole blood. A solid-phase extraction (SPE) procedure using HF Bond Elut C18 columns followed by derivatization using N-methyl-N-tert-butyldimethylsilyl-trifluoroacetamide (MTBSTFA) with 1% tert-butyldimethylsilyl chloride (TBDMSCl) was used. In this assay, levetiracetam-d6 was used as internal standard. Limits of detection and quantification were 0.15 and 0.50 μg/mL, respectively, for both analytes. The method was proved to be linear within the concentration range of 0.50-50.0 μg/mL (R(2) ≥ 0.992) for both analytes. Absolute recovery was found to be at least 90.0 and 97.2% for levetiracetam and lamotrigine, respectively. Intra-day and inter-day accuracy values for both analytes were ranged from -6.5 to 4.2 and -6.6 to 3.0%, respectively, whereas their respective precision values were less than 11.4 and 8.3%. The developed method was successfully used in our laboratory for quantification of levetiracetam and lamotrigine blood concentrations during the investigation of forensic cases where these antiepileptic drugs were involved. This method could also be used for therapeutic drug monitoring purposes.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M108
(−)-MK-801 hydrogen maleate, ≥98% (HPLC)
C16H15N · C4H4O4
470961
2,2,3,3,3-Pentafluoropropyl acrylate, 98%, contains 100 ppm 4-tert-butylcatechol as inhibitor
C6H5F5O2
691275
Acetic anhydride, Lonza quality, ≥99.5% (GC)
C4H6O3
A6404
Acetic anhydride, reagent grade, ≥98%
C4H6O3
45840
Acetic anhydride
C4H6O3
01-0390
Acetic anhydride, SAJ first grade, ≥93.0%
C4H6O3
01-0380
Acetic anhydride, JIS special grade
C4H6O3
L095004
Acetic anhydride
C4H6O3
386529
Chlorotrimethylsilane, purified by redistillation, ≥99%
C3H9ClSi
95541
Chlorotrimethylsilane, produced by Wacker Chemie AG, Burghausen, Germany, ≥99.0% (GC)
C3H9ClSi
92361
Chlorotrimethylsilane, ≥98.0% (GC)
C3H9ClSi
92360
Chlorotrimethylsilane, puriss., ≥99.0% (GC)
C3H9ClSi
89595
Chlorotrimethylsilane, for GC derivatization, ≥99.0% (GC)
C3H9ClSi
385433
Chlorotrimethylsilane solution, 1.0 M in methylene chloride
C3H9ClSi
384410
Chlorotrimethylsilane solution, 1.0 M in THF
C3H9ClSi
H1006
Heptafluorobutyric anhydride, ≥98%
C8F14O3
394912
Heptafluorobutyric anhydride, for GC derivatization, ≥99.0%
C8F14O3
77253
Heptafluorobutyric anhydride, for GC derivatization, ≥99.0%
C8F14O3
L3791
Lamotrigine, ≥98%, powder
C9H7Cl2N5
Y0001030
Lamotrigine, European Pharmacopoeia (EP) Reference Standard
C9H7Cl2N5
1356756
Lamotrigine, United States Pharmacopeia (USP) Reference Standard
C9H7Cl2N5
PHR1392
Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material
C9H7Cl2N5
Y0001031
Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard
C9H7Cl2N5
Y0001085
Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard
C9H7Cl2N5
34148
Metolachlor OA, PESTANAL®, analytical standard
C15H21NO4
15222
N,O-Bis(trimethylsilyl)trifluoroacetamide, for GC derivatization, ≥99.0%
C8H18F3NOSi2
155195
N,O-Bis(trimethylsilyl)trifluoroacetamide, ≥99%
C8H18F3NOSi2
394653
N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane, with 10% trimethylchlorosilane, for GC derivatization, ≥98.0%
C8H18F3NOSi2
T6381
N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane, with 1% trimethylchlorosilane, for GC derivatization
C8H18F3NOSi2
15238
N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane, for GC derivatization, contains 1% TMCS, 99% (excluding TMCS)
C8H18F3NOSi2